Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Children and Young Adults With Refractory Solid Tumors
NCT01956669Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of pazopanib in rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), Ewing sarcoma, Peripheral Primitive Neuroectodermal Tumor (pPNET), osteosarcoma (OS), sponsored by Novartis. Started Oct 2014; status: completed.
02
Drugs
pazopanib
03
Conditions
rhabdomyosarcoma (RMS)soft tissue sarcoma (STS)Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT01956669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01956669.